Find in Library

P809: BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE-CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS

oleh: Afshin Mashadi-Hossein, Julie Rytlewski, MD Shamsuzzaman, Debashree Basudhar, Mandeep Takhar, Ana Kostic, Timothy B. Campbell, Salomon Manier, Yi Lin, Nathan Martin